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A B S T R A C T
Aquaglyceroporin-2 is a known determinant of melarsoprol–pentamidine cross-resistance in Trypano-
soma brucei brucei laboratory strains. Recently, chimerization at the AQP2–AQP3 tandem locus was described
frommelarsoprol–pentamidine cross-resistant Trypanosoma brucei gambiense isolates from sleeping sick-
ness patients in the Democratic Republic of the Congo. Here, we demonstrate that reintroduction of wild-
type AQP2 into one of these isolates fully restores drug susceptibility while expression of the chimeric
AQP2/3 gene in aqp2–aqp3 null T. b. brucei does not. This proves that AQP2–AQP3 chimerization is the
cause of melarsoprol–pentamidine cross-resistance in the T. b. gambiense isolates.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Trypanosoma brucei gambiense is the causative agent of West-
African sleeping sickness and responsible for 98% of today’s cases
of human African trypanosomiasis (HAT) (Brun et al., 2010). HAT
is a fatal disease whose treatment exclusively relies on chemother-
apy. Only ﬁve drugs are available: suramin and pentamidine for the
ﬁrst, haemolymphatic stage of the disease, melarsoprol and
nifurtimox/eﬂornithine combination therapy for the second stage,
when the parasites have infested the central nervous system. These
drugs cause severe side effects and are diﬃcult to administer (Brun
et al., 2010). New drug candidates are in clinical development (Mäser
et al., 2012), but until they are available for treatment, the current
drugs must be used sustainably. Therefore understanding the mo-
lecular mechanism of drug resistance is a prerequisite. Drug
resistance studies with Trypanosoma brucei brucei lab strains have
identiﬁed loss of drug uptake as the major mechanism of drug re-
sistance in trypanosomes. This is due tomutations in the transporters
responsible for drug uptake. The clinical drugsmelarsoprol and pent-
amidine share two common transporter systems, the adenosine
transporter 1 (TbAT1, also called P2; Carter and Fairlamb, 1993; Carter
et al., 1995; Mäser et al., 1999) and aquaglyceroporin 2 (Baker et al.,
2012). Genetic knock-out of either transporter gene, but particu-
larly of AQP2, led to melarsoprol–pentamidine cross-resistance
(MPXR) (Matovu et al., 2003; Baker et al., 2012, 2013).
Drug resistance of T. b. gambiense in the ﬁeld has been contro-
versial. The occurrence of mutant TbAT1 alleles correlated to some
extent with melarsoprol treatment failures (Matovu et al., 2001;
Maina et al., 2007; Kazibwe et al., 2009), but no unambiguous genetic
marker for resistance has been established so far. Recently, muta-
tions at the AQP2–AQP3 (Tb927.10.14170/Tb927.10.14160) tandem
locus were found in T. b. gambiense isolates from the Democratic
Republic of the Congo (Graf et al., 2013). In particular, a set of 41
isolates from Mbuji-Mayi, a HAT focus of exceptionally high
melarsoprol treatment failure rates (Pyana et al., 2014), all carried
a chimeric aquaglyceroporin, presumably formed by homologous
recombination between AQP2 and AQP3; a putative single-strand
annealingmechanism accompanied by deletion of segments of AQP2
and AQP3 (Graf et al., 2013). The AQP2/3(814) chimera, the ﬁrst 813
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b derived from AQP2 and the last 126 b from AQP3, was in-frame,
transcribed and homozygous. A second AQP2/3 chimeric gene, AQP2/
3(880) with just the last 60 bp derived from AQP3, had been described
in the T. b. gambiense isolates fromMbuji-Mayi (Pyana et al., 2014).
In the present study we did not detect the AQP2/3(880) gene either
with direct sequencing of PCR products or after cloning of the PCR
products into expression vectors. The isolates carrying the chime-
ric gene exhibited a markedly decreased melarsoprol sensitivity in
vivo (Pyana et al., 2014). Those that were tested in vitro were cross-
resistant to melarsoprol and pentamidine; to our knowledge, the
ﬁrst example of MPXR from clinical T. b. gambiense isolates (Graf
et al., 2013).
Thus, the important question remained: Is the MPXR pheno-
type of the T. b. gambiense isolates from Mbuji-Mayi caused by the
observed chimerization at the AQP2–AQP3 locus? And if so, is it the
presence of the AQP2/3(814) chimera or the absence of wild-type AQP2
that causes drug resistance? Here, we answer these questions by
(i) re-introducing wild-type AQP2 into one of the mutant
T. b. gambiense isolates and (ii) expressing the chimeric AQP2/3(814)
gene from T. b. gambiense in T. b. brucei.
2. Materials and methods
2.1. Cell lines, cell culture and in vitro drug sensitivity assay
T. b. brucei 2T1 cells (Alsford et al., 2005) and 2T1 aqp2–aqp3
double knock-out cells (Alsford et al., 2012) weremaintained in HMI-
11medium. Puromycin (0.2 μg/ml) and phleomycin (0.5 μg/ml) were
added for 2T1 cells. For 2T1 aqp2–aqp3 double knock-out cells
blasticidin (10 μg/ml) and G418 (2 μg/ml) were added in addition.
Hygromycin (2.5 μg/ml), instead of puromycin, was added after trans-
fection with chimeric AQP2/3(814). T. b. gambiense 40AT (MHOM/CD/
INRB/2006/07; Pyana et al., 2011) were cultured in HMI-9 medium
with 15% FCS and 5% human serum, plus blasticidin (5 μg/ml) after
transfection. In vitro drug sensitivities were determined as de-
scribed (Graf et al., 2013). For the inducible cells, 1 μg/ml tetracycline
(tet) was added 24 h prior to the assay.
2.2. Plasmids and transfection
The chimeric AQP2/3(814) gene (GenBank accession KF564935) was
ampliﬁed by PCR with primers AQP_HindIII_F (ccgcaagcttatgca
gagccaaccagac) and AQP_BamH1_R (ccgcggatccttagtgtggcacaaaatatt),
or AQP_Xba1_F (ccgctctagaatgcagagccaaccagac) and AQP_BamH1_R,
and cloned into the pRPa-series of tetracycline-inducible expres-
sion vectors (http://www.lifesci.dundee.ac.uk/groups/david-horn/
resources). Vector inserts were checked for ﬁdelity by Sanger se-
quencing (Microsynth). Bloodstream-form T. b. brucei were
transfected as previously described (Baker et al., 2012). Clones were
obtained by limiting dilution in standard HMI-11 medium plus an-
tibiotics (see above). The AQP2 gene was ampliﬁed from wild-type
T. brucei 427 parasites and the AQP2/3(569–841) gene from the derived,
pentamidine-resistant, strain B48, using proof-reading poly-
merase and oligonucleotides which added an ApaI site to the 5′ end
and a BamHI site to the 3′ end of the genes. The genes were ligated
into pGEM-T Easy vector, and digested out using the added restric-
tion sites. They were then ligated into similarly digested pHD1336
vector, to give plasmids pHDK21 (AQP2) and pHDK34 (AQP2/3(569–841)).
Both plasmids were checked by Sanger Sequencing (Euroﬁns MWG
Operon). Bloodstream-form T. b. gambiense were transfected with
pHDK21 and pHDK34 as follows: 4 × 107 cells were resuspended in
100 μl Tb-BSF nucleofection buffer (Schumann Burkard et al., 2011)
(90 mM NaHPO3, 5 mM KCl, 0.15 mM CaCl2, 50 mM HEPES, pH 7.3)
including 10 μg linearized plasmid DNA and placed in the
nucleofection cuvette in the Amaxa Nucleofector (Lonza). Cells were
electroporated using the program Z-001 and immediately trans-
ferred into 25ml of pre-warmed HMI-9medium containing 15% FCS,
5% human serum, and 20% sterile-ﬁltered conditioned medium.
Stable clones were obtained by limiting dilution and blasticidin se-
lection (5 μg/ml). Correct integration was assessed by PCR on
genomic DNA with primers AQP2_int_F (gtattggtgtggctgtcacg),
AQP3_int_R (cccgttgagtaaccgatgtt), pAQP_F (aacacaccggtaccgtcatt)
and pAQP_R (cttctcttgtgcgctgtacg).
Western blots of GFP-AQP2/3(814) in 2T1 aqp2–aqp3 null cells were
performed as described (Baker et al., 2012). Western blots with GFP-
AQP2/3(814) in 2T1 wild-type cells were performed as follows: cells
were lysed in NUPAGE® LDS sample buffer (Life Technologies),
samples separated on precast 4–12% Bis-Tris Gradient Gels (NuPAGE
Novex®, Life Technologies) and transferred to nitrocellulose
membranes using the iBlot dry-blotting system (Novex®, Life Tech-
nologies) according to themanufacturer’s recommendations.Western
blots were developed with the ECL Western Blotting Substrate
(Pierce) using a ChemiDoc™ MP Gel Imaging System (Biorad).
Primary Antibody: rabbit anti-GFP (Abcam, Ab290); secondary an-
tibody: goat anti-rabbit (SouthernBiotech, 4050-05).
3. Results and discussion
3.1. Expression of wild-type AQP2 re-sensitizes drug-resistant
T. b. gambiense
To test whether the lack of bona ﬁde AQP2 activity contributes
to drug resistance in the isolates from Mbuji-Mayi, we introduced
a ‘wild-type’ copy of AQP2 into T. b. gambiense 40AT, isolated from
a melarsoprol-relapse patient after treatment (Pyana et al., 2011).
The gene was integrated into the highly transcribed rRNA-spacer
locus. This shifted the IC50 of pentamidine from 108 nM to 2 nM and
the IC50 of melarsoprol from 47 nM to 10 nM (Fig. 1), a level similar
to the fully susceptible T. b. gambiense reference isolate STIB930
(which had an IC50 of 2 nM for pentamidine and 10 nM for
melarsoprol; Graf et al., 2013). No shifts were observed with
diminazene aceturate, a diamidine that is not an AQP2 substrate
(Munday et al., 2014), or with phenylarsine oxide (data not shown),
an arsenical that diffuses through the plasma membrane. The same
results were obtained with three additional clones. As a negative
control, we transfected the 40AT cells with a non-functional AQP2
mutant from the MPXR T. b. brucei clone B48 (Munday et al., 2014).
As expected, this did not affect susceptibility to melarsoprol or pent-
amidine (Fig. 1). These results demonstrate that AQP2 is key to drug
susceptibility in the MPXR T. b. gambiense isolate.
3.2. Expression of the chimeric AQP2/3(814) in an aqp2–aqp3
null background
To test whether the chimeric AQP2/3(814) can complement AQP2
function with regard to drug uptake, we stably integrated the chi-
meric AQP2/3(814) gene from T. b. gambiense 40AT, either untagged
or GFP-tagged, under the control of the tetracycline operator in a
T. b. brucei host strain that expressed the tet repressor, and that
carried a complete deletion of the AQP2–AQP3 locus (Alsford et al.,
2011). Tetracycline-inducible (1 μg/ml) expression of the chimeric
AQP2/3(814) protein was conﬁrmed by immuno-ﬂuorescence mi-
croscopy (data not shown) and by Western blotting with an anti-
GFP antibody (Fig. 2C). Drug sensitivities were determined in vitro
for melarsoprol and pentamidine. None of the transfected cell lines
showed a signiﬁcant difference in IC50 to pentamidine or melarsoprol
when expression of AQP2/3(814) had been induced with tetracy-
cline as compared to non-induced cells (Fig. 2A). This held true
irrespective of the presence of the GFP tag. Thus no potential func-
tion in drug susceptibility could be attributed to the AQP2/3 chimera.
Expression of ‘wild-type’ AQP2 using the same over-expression
system (untagged and GFP-tagged) did not just reverse MPXR but
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actually hypersensitized the aqp2–aqp3 double null T. b. brucei to
pentamidine and melarsoprol (Baker et al., 2012).
3.3. Expression of chimeric AQP2/3(814) in wild-type cells does not
affect drug sensitivity
Aquaporins form homotetramers where each monomer consti-
tutes a single pore. Work on human aquaporins involved in diabetes
insipidus has revealed that the expression of a mutant aquaporin
can give rise to dominant negative effects (Mulders et al., 1998). To
test for negative interactions of AQP2/3(814) with ‘wild-type’ AQP2,
the chimera was expressed in parental T. b. brucei 2T1 cells. The same
tetracycline-inducible over-expression system was used. Again, no
signiﬁcant difference was observed regarding sensitivity to pent-
amidine and melarsoprol in tetracycline-induced versus uninduced
cells (Fig. 2B). Hence, the AQP2/3(814) chimera does not interfere with
endogenous AQP2 function in T. b. brucei bloodstream-form cells.
4. Conclusion
Previous work on the correlation of occurrence of the chimeric
AQP2/3(814) gene in T. b. gambiense isolates from the DRC with in vitro
drug sensitivity (Graf et al., 2013) suggested a functional link between
the chimera and MPXR. However, proof of a causal relationship was
Fig. 1. Introduction of AQP2 into mutant T. b. gambiense. In vitro drug sensitivity of bloodstream-form T. b. gambiense 40AT (grey) transfected with AQP2 (black) or dysfunc-
tional AQP2 (ctrl, dark grey). Error bars are standard errors of the mean. n = 6 independent experiments, each in duplicate. Small letters indicate signiﬁcance groups as determined
by one-way ANOVA and Tukey’s post test using GraphPad Prism 5.0.
Fig. 2. Expression of the AQP2/3(814) chimera in T. b. brucei. In vitro drug sensitivity of bloodstream-form T. b. brucei 2T1 aqp2–aqp3 double null mutants (A) and parental
2T1 cells (B) transfected with a tetracycline (tet) inducible AQP2/3(814) chimera. Dark bars, tet (1 μg/ml) was added 24 h prior to the drug assay. Error bars are standard error
of the mean. n = 4–5 independent experiments, each in duplicate. (C) Western blot with anti-GFP antibody demonstrating inducible expression of GFP-tagged AQP2/3(814)
(Coo, Coomassie stain). The GFP-AQP2/3(814) fusion proteins ran below their predicted molecular mass (approximately 60 kDa), which often applies for proteins with many
transmembrane domains. The lower of the inducible bands in the blot on the right may represent unprocessed (e.g. unglyosylated) GFP-AQP2/3.
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lacking. The AQP2/3(814) chimeric protein consists mostly of AQP2
sequence, including the atypical second ﬁlter sequence (Baker et al.,
2012). Overall, AQP2/3(814) of the T. b. gambiense from Mbuji-Mayi
has only 9 amino acid differences with AQP2. Moreover, the differ-
ent T. b. gambiense isolates that harboured the chimeric gene were
probably of clonal origin (Pyana et al., 2015) and may therefore not
count as independent samples for the correlation of AQP2/3(814) geno-
type to MPXR phenotype. Thus reverse genetic engineering of
bloodstream-form trypanosomes was required to establish a direct
link between chimerization at the AQP2–AQP3 locus in T. b. gambiense
isolates and MPXR. This was only feasible because some of the iso-
lates from Mbuji-Mayi had been adapted to axenic growth in vitro
(Pyana et al., 2011).
The MPXR T. b. gambiense isolate 40AT was completely re-
sensitized to melarsoprol and pentamidine when transfected with
a wild-type copy of AQP2. This proves that the observed
chimerization at the AQP2–AQP3 locus is indeed the genetic basis
of MPXR. The AQP2/3(814) chimeric protein did not exhibit any role
in conferring drug sensitivity when over-expressed in T. b. brucei,
neither in a aqp2–aqp3 null background nor in the AQP2–AQP3wild-
type background. This further demonstrates that it is the absence
of ‘wild-type’ AQP2, and not the presence of the AQP2/3(814) chimera,
that causes the MPXR phenotype. Deletion-based gene-fusion at the
AQP2–AQP3 locus by homologous recombination is likely facili-
tated by the high degree of sequence identity between AQP2 and
AQP3. Taken together, our ﬁndings strongly indicate that
chimerization at the AQP2–AQP3 locus causes melarsoprol–
pentamidine cross-resistance in T. b. gambiense. This consequently
increases the risk of treatment failures in problematic HAT foci such
as Mbuji-Mayi of the Democratic Republic of the Congo. This is the
ﬁrst example where a genetic basis for drug-resistant sleeping sick-
ness has been conﬁrmed.
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